GlassScriptPhysician profile
Artemus Flagg
NPI 1427161157
$3,436.31
in general payments reported to CMS, 2019-2025
27 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $293 · 2021: $240 · 2022: $962 · 2023: $37.99 · 2024: $927 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $688 · Honoraria: $600 · Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $687.77 |
| Honoraria | $600.00 |
| Food and Beverage | $419.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $837.69 | 2022 | |
| Curonix LLC | $824.46 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Protega Pharmaceutials INC | $600.00 | 2025 | Roxybond |
| Nevro Corp. | $268.33 | 2019-2022 | |
| Boston Scientific Corporation | $154.81 | 2019-2022 | |
| Saluda Medical Americas, INC. | $91.41 | 2025 | Evoke |
| Abbott Laboratories | $81.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $70.44 | 2021 | |
| Nalu Medical, INC. | $67.25 | 2021-2024 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $62.85 | 2020 | |
| Stratus Medical, LLC | $60.17 | 2020 | |
| Medtronic, INC. | $37.44 | 2021 | |
| Virtus Pharmaceuticals LLC | $37.34 | 2024-2025 | Levorphanol Tartrate |
| Vertiflex, INC. | $32.45 | 2019 | |
| Forte Bio-Pharma LLC | $21.06 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $19.37 | 2023 | Qutenza |
| Bioventus LLC | $19.08 | 2025 | Durolane |
| Scilex Pharmaceuticals INC. | $18.62 | 2023 | Ztlido |
| Valinor Pharma, LLC | $17.92 | 2024 | Movantik |
| Horizon Therapeutics Plc | $17.58 | 2022 | |
| Convatec INC. | $16.69 | 2025 | |
| Pfizer INC. | $15.72 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.54 | 2024 | Relistor |
| Biodelivery Sciences International, INC. | $13.28 | 2019 | |
| Redhill Biopharma INC. | $12.96 | 2020 | |
| Allergan, INC. | $12.56 | 2020 | |
| Stimwave Technologies Incorporated | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Artemus Flagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.